Dr. Wedam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8901 Wisconsin Ave
Bldg 8, Rm 5101
Bethesda, MD 20889Phone+1 301-496-0901Fax+1 301-496-0047
Education & Training
- MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1997 - 2001
- Georgetown University School of MedicineClass of 1997
Certifications & Licensure
- VA State Medical License 1997 - 2026
- DC State Medical License 1999 - 2000
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer Start of enrollment: 2001 May 13
- Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer Start of enrollment: 2003 Nov 01
Publications & Presentations
PubMed
- 180 citationsCDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled a...Jennifer J Gao, Joyce Cheng, Erik Bloomquist, Jacquelyn Sanchez, Suparna Wedam
The Lancet. Oncology. 2020-02-01 - 29 citationsFDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast CancerMirat Shah, Suparna Wedam, Joyce Cheng, Mallorie H. Fiero, Huiming Xia
Clinical Cancer Research. 2021-03-01 - 111 citationsFirst FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast CancerLaleh Amiri-Kordestani, Suparna Wedam, Lijun Zhang, Shenghui Tang, Amy Tilley
Clinical Cancer Research. 2014-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: